The global carrier screening market is on a strong upward trajectory, driven by rising genetic disorder prevalence, advancing sequencing technologies, and growing pre-pregnancy awareness worldwide. According to Fortune Business Insights, the market was valued at USD 1.70 billion in 2025 and is projected to grow from USD 1.88 billion in 2026 to USD 3.08 billion by 2034, registering a CAGR of 6.4% during the forecast period.
Carrier screening is a genetic test that determines whether an individual carries a gene mutation linked to an inherited disorder—even if they show no symptoms. It is typically recommended before or during pregnancy to assess the risk of passing recessive genetic conditions to a child. With approximately 7.9 million births annually involving genetic or partially genetic defects (WHO, 2025), demand for carrier screening services continues to grow globally.
Technological advancement is one of the most powerful engines of market growth. The widespread adoption of next-generation sequencing (NGS) has dramatically reduced the cost per test—sequencing costs fell by over 40% between 2018 and 2023—enabling laboratories to shift from single-gene PCR tests to broad expanded carrier screening (ECS) panels. These panels simultaneously screen hundreds of conditions, regardless of a patient's ethnic background.
Updated guidelines from the American College of Medical Genetics and Genomics (ACMG) in 2021 recommending ECS for all individuals planning pregnancy further accelerated adoption across the U.S., Europe, and parts of Asia. The integration of carrier screening into standard IVF protocols has also amplified demand—according to the American Society for Reproductive Medicine (ASRM), IVF cycles at SART-member clinics rose from 389,993 in 2022 to 432,641 in 2023.
Despite strong momentum, cost remains a barrier. ECS panels range from USD 250 to USD 600 in many regions, and reimbursement policies vary widely. Countries like the U.S. and Australia offer subsidies, while many systems across Asia, Latin America, and Africa provide minimal coverage. A shortage of qualified genetic counselors—especially in high-growth fertility markets like India and Southeast Asia—also constrains wider adoption.
North America leads with a 40% global market share in 2025 (USD 0.68 billion), backed by strong reimbursement frameworks and high NGS adoption. Europe is expected to reach USD 0.50 billion in 2026, led by Germany, France, and the U.K. Asia Pacific is emerging as the second-largest region, projected at USD 0.34 billion in 2026, with China and India as key contributors. The Middle East is expanding through government-backed premarital screening programs in UAE, Saudi Arabia, and Qatar.
Prominent companies operating in the global carrier screening market include:
Q1. What is the size and share of the carrier screening market? According to Fortune Business Insights, the global carrier screening market was valued at USD 1.70 billion in 2025 and is projected to reach USD 3.08 billion by 2034, growing at a CAGR of 6.4%. North America holds the dominant regional share at 40% of the global market in 2025, followed by Europe and Asia Pacific.
Q2. What technology leads the carrier screening market? Next-generation sequencing (NGS) is the leading technology, accounting for 73.3% of the market in 2025. Its dominance is driven by declining sequencing costs, wider ECS panel capabilities, and growing reimbursement support for NGS-based tests.
Q3. What are the key growth opportunities in the carrier screening market? Significant growth opportunities lie in emerging markets across Asia Pacific, Latin America, and the Middle East, where rising IVF adoption, government-backed genetic health programs, and growing awareness of hereditary diseases are expected to drive expanded market penetration over the forecast period.
Source: Fortune Business Insights – Carrier Screening Market Report URL: https://www.fortunebusinessinsights.com/carrier-screening-market-114944